Citius Pharmaceuticals Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
/ 
Frequently asked questions
To buy Citius Pharmaceuticals Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Citius Pharmaceuticals Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Citius Pharmaceuticals Inc. is CTXR:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Citius Pharmaceuticals Inc. has its primary listing on NASDAQ (Small cap). You can trade Citius Pharmaceuticals Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Citius Pharmaceuticals Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Citius Pharmaceuticals Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Citius Pharmaceuticals Inc..